GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, has announced it will release its third quarter 2024 financial results before the market opens on Tuesday, October 29, 2024. The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results.
Investors interested in participating in the conference call must register online. A live and archived webcast of the event will be available on the 'Events' section of GeneDx's investor relations website at https://ir.genedx.com/.
GeneDx specializes in rare disease diagnostics, offering exome and genome tests that translate complex genomic data into clinical answers. The company aims to provide personalized, targeted medical care through genetic diagnosis.
GeneDx (Nasdaq: WGS), un leader nell'analisi genomica per il miglioramento dei risultati sanitari, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato il martedì 29 ottobre 2024. L'azienda ospiterà una conferenza telefonica alle 8:30 a.m. Eastern Time lo stesso giorno per discutere i risultati.
Gli investitori interessati a partecipare alla conferenza telefonica devono registrarsi online. Una registrazione in diretta e archiviata dell'evento sarà disponibile nella sezione 'Eventi' del sito web delle relazioni con gli investitori di GeneDx all'indirizzo https://ir.genedx.com/.
GeneDx si specializza nella diagnostica delle malattie rare, offrendo test sull'exoma e sul genoma che traducono dati genomici complessi in risposte cliniche. L'azienda mira a fornire cure mediche personalizzate e mirate attraverso la diagnosi genetica.
GeneDx (Nasdaq: WGS), un líder en conocimientos genómicos para mejorar los resultados de salud, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el martes 29 de octubre de 2024. La empresa realizará una conferencia telefónica a las 8:30 a.m. Eastern Time el mismo día para discutir los resultados.
Los inversores interesados en participar en la conferencia telefónica deben registrarse en línea. Una transmisión en vivo y archivada del evento estará disponible en la sección 'Eventos' del sitio web de relaciones con inversores de GeneDx en https://ir.genedx.com/.
GeneDx se especializa en diagnósticos de enfermedades raras, ofreciendo pruebas de exoma y genoma que traducen datos genómicos complejos en respuestas clínicas. La empresa busca proporcionar atención médica personalizada y dirigida a través del diagnóstico genético.
GeneDx (Nasdaq: WGS)는 건강 결과 향상을 위한 유전체 통찰의 선두주자로서 2024년 3분기 재무 실적을 2024년 10월 29일 화요일 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 동일한 날 동부 표준시 오전 8시 30분에 실적을 논의하기 위해 전화 회의를 주최할 것입니다.
전화 회의에 참여하려는 투자자는 온라인으로 등록해야 합니다. 이 이벤트의 실시간 및 아카이브 웹 캐스트는 GeneDx의 투자자 관계 웹사이트 '이벤트' 섹션(https://ir.genedx.com/)에서 사용할 수 있습니다.
GeneDx는 희귀 질병 진단을 전문으로 하며, 복잡한 유전체 데이터를 임상적으로 해석할 수 있는 엑소좀 및 게놈 검사를 제공합니다. 이 회사는 유전자 진단을 통해 개인 맞춤형, 표적 의료 서비스를 제공하는 것을 목표로 하고 있습니다.
GeneDx (Nasdaq: WGS), un leader dans les informations génomiques pour améliorer les résultats de santé, a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture du marché le mardi 29 octobre 2024. L'entreprise tiendra une conférence téléphonique à 8h30 heure de l'Est le même jour pour discuter des résultats.
Les investisseurs intéressés par la participation à la conférence téléphonique doivent s'inscrire en ligne. Un webinaire en direct et en archive de l'événement sera disponible dans la section 'Événements' du site web des relations avec les investisseurs de GeneDx à l'adresse https://ir.genedx.com/.
GeneDx se spécialise dans le diagnostic des maladies rares, offrant des tests d'exome et de génome qui traduisent des données génomiques complexes en réponses cliniques. L'entreprise vise à fournir des soins médicaux personnalisés et ciblés grâce au diagnostic génétique.
GeneDx (Nasdaq: WGS), ein führendes Unternehmen im Bereich genomischer Einsichten zur Verbesserung von Gesundheitsergebnissen, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am Dienstag, den 29. Oktober 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Investoren, die an der Telefonkonferenz teilnehmen möchten, müssen sich online registrieren. Eine Live- und Archiv-Übertragung der Veranstaltung wird im Bereich 'Veranstaltungen' auf der Investor Relations-Website von GeneDx unter https://ir.genedx.com/ verfügbar sein.
GeneDx ist auf die Diagnostik seltener Krankheiten spezialisiert und bietet Exom- und Genomtests an, die komplexe genomische Daten in klinische Antworten übersetzen. Das Unternehmen hat sich zum Ziel gesetzt, personalisierte, zielgerichtete medizinische Versorgung durch genetische Diagnosen bereitzustellen.
- None.
- None.
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003803932/en/
Investor Relations Contact:
investors@GeneDx.com
Media Contact:
press@GeneDx.com
Source: GeneDx
FAQ
When will GeneDx (WGS) release its Q3 2024 financial results?
What time is GeneDx's (WGS) Q3 2024 earnings conference call?
Where can investors find the webcast for GeneDx's (WGS) Q3 2024 earnings call?
What is GeneDx's (WGS) stock symbol?
